Details for Patent: 5,716,933
✉ Email this page to a colleague
| Title: | Process for the long term reduction of body fat stores, insulin resistance, and hyperinsulinemia in vertebrates |
| Abstract: | A process for the long term modification and regulation of lipid metabolism--generally to reduce obesity, insulin resistance, and hyperinsulinemia (the three hallmarks of Type II diabetes)--by injections into the bloodstream of a vertabrate, animal or human, of prolactin, or both prolactin and a glucocorticosteroid. The injections are made over a limited period at a time of day dependent on the normal circadian rhythm of fat and lean members of a similar species. Decreases (or increases) in body fat deposits result by treatment of an obese species (lean species) on a daily timed sequence based on circadian rhythms of the peak prolactin, or peak prolactin and peak glucocorticosteroid, blood level established for lean members (or obese members) of a similar species. Insulin resistance, and hyperinsulinemia can also be controlled in humans on a long term basis by treatment corresponding to that of the treatment for obesity. The short term daily injections reset hormonal timing in the neural centers of the brain to produce long term effects. |
| Inventor(s): | Meier; Albert H. (Baton Rouge, LA), Cincotta; Anthony H. (Baton Rouge, LA) |
| Assignee: | Louisiana State University and Agricultural and Mechanical College (Baton Rouge, LA) |
| Filing Date: | May 26, 1995 |
| Application Number: | 08/452,388 |
| Claims: | 1. A process for modifying and resetting the prolactin and glucocorticosteriod rhythms in an obese animal, or obese human, which comprises injecting prolactin into the blood of the animal, or human, on a daily basis at the time of day when the prolactin level will peak in the blood of a lean insulin sensitive human, in dosage amount ranging from about 175 micrograms to about 2000 micrograms, per pound of body weight, and injecting a glucocorticosteroid into the blood of the animal, or human, on a daily basis at the time of day when the cortisol level will peak in the blood of a lean insulin sensitive human, in dosage amount ranging from about 175 to 2000 micrograms, per pound of body weight and continuing the injections over a period sufficient to reduce the fat deposits in the body of the obese animal, or person, to that of a lean animal, or person. 2. The process of claim 1 wherein the prolactin and glucocorticosteroid are injected daily into the bloodstream of a lean animal, or person at the time of day corresponding to that at which the prolactin and cortisol levels, respectively, will peak in a fat animal, or person, to increase the body fat content of the lean animal, or person. 3. The process of claim 1 wherein the prolactin and glucocorticosteroid are injected daily into the bloodstream of a human to increase the cellular sensitivity of the treated human to insulin. 4. The process of claim 1 wherein the prolactin and glucocorticosteroid are injected daily into the bloodstream of a human to reduce hyperinsulinemia. |
